Lundbeckfonden BioCapital
Copenhagen, DenmarkFounded 2022
Lundbeckfonden BioCapital is the venture capital arm of the Lundbeck Foundation, operating as an evergreen fund that invests in life science companies to support the translation and commercialization of groundbreaking science, primarily in Denmark.
38% of their portfolio is in Biotech & Life Sciences. Average disclosed round size is $31.3M (across 3 rounds with reported amounts).
Portfolio
8
Fund Size
—
Top Stage
Series B
Last 12 Mo
0
Team
Portfolio Breakdown
Stage Distribution
Investment Activity
DealsAvg Round Size
Portfolio
8 investments
| Company | Round | Amount | Date |
|---|---|---|---|
 SNIPR Biome | Series B | — | Aug 2025 |
 NMD Pharma | Series B | — | Nov 2023 |
 Cytoki Pharma | Series A | $45M | Jan 2021 |
| TTiburio | Series A | $31M | Jan 2019 |
| VVarmX BV | Series B | — | — |
| NNotify Therapeutics | Unknown | — | — |
| DDysis Medical | Unknown | $18M | — |
| DDania Therapeutics | Unknown | — | — |
Top Co-Investors
EQT Life Sciences2 shared
INKEF Capital2 shared
Ysios Capital2 shared
+ND Capital2 shared
Wellington Management1 shared
Cystic Fibrosis Foundation1 shared
Roche Venture Fund1 shared
Jeito Capital1 shared
Novo Capital1 shared
Novo Holdings A/S1 shared
BioGeneration Ventures1 shared
InnovationQuarter1 shared
European Commission1 shared
Longitude Capital1 shared
New Enterprise Associates1 shared
Alexandria Venture Investments1 shared
EIFO1 shared
Seventure Partners1 shared
Last updated: 20 October 2026